Business briefs: GlaxoSmithKline and Spectrum

Share this article:

GlaxoSmithKline said the PDUFA goal date for albiglutide, its investigational once-weekly GLP-1 treatment for adult patients with type 2 diabetes, has been extended by three months to April 15, 2014, “to provide time for a full review of information submitted by GSK in response to the [FDA's] requests.” GSK filled a BLA to the FDA for albiglutide in January, followed by a submission to the EMA in March. GSK said the EMA filing is “progressing to schedule.” The drug would compete with BMS/AZ's Bydureon, also a once-weekly shot.

A professional sales aid from Spectrum Pharmaceuticals' cancer infusion Zevalin minimized risk information, overstates efficacy and omits material facts, said OPDP in an untitled letter dated July 23 and recently posted on the FDA website. OPDP said the conduct occurred despite repeated advisory comments addressing similar misleading presentations on five other occasions.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.